- Home
- Publications
- Publication Search
- Publication Details
Title
Ustekinumab: a novel therapeutic option in Crohn’s disease
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 16, Issue 8, Pages 1065-1074
Publisher
Informa UK Limited
Online
2016-06-24
DOI
10.1080/14712598.2016.1205582
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents
- (2016) Pauline Wils et al. Clinical Gastroenterology and Hepatology
- 696 Association of Ustekinumab Trough Concentrations With Clinical, Biochemical and Endoscopic Outcomes
- (2016) Robert Battat et al. GASTROENTEROLOGY
- Tu2006 Ustekinumab Improves General Health Status and Disease-Specific Health Related Quality of Life of Patients with Moderate to Severe Crohn's Disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials
- (2016) Bruce E. Sands et al. GASTROENTEROLOGY
- Patients with Refractory Crohnʼs Disease Successfully Treated with Ustekinumab
- (2016) Kimberly A. Harris et al. INFLAMMATORY BOWEL DISEASES
- O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα
- (2016) William Sandborn et al. INFLAMMATORY BOWEL DISEASES
- Ustekinumab for Resistant Pediatric Crohn Disease
- (2016) Firas Rinawi et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Sa1211 Assessment of Sleep Impairment in Patients With Crohn's Disease: Results From the Ustekinumab Certifi Study
- (2015) Christopher Gasink et al. GASTROENTEROLOGY
- Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
- (2014) Denis Poddubnyy et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis
- (2014) M. A. Judson et al. EUROPEAN RESPIRATORY JOURNAL
- Su1420 Ustekinumab Treatment for Crohn's Disease in Clinical Practice: Experience At a Tertiary Medical Center
- (2014) Daisy D. Batista et al. GASTROENTEROLOGY
- Demyelination in a patient receiving ustekinumab for refractory Crohn's disease: Figure 1
- (2014) Yaeesh Badat et al. Journal of Crohns & Colitis
- Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—The McGill experience
- (2014) U. Kopylov et al. Journal of Crohns & Colitis
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Predictors of favourable outcome in inflammatory Crohn's disease. A retrospective observational study
- (2013) Yamile Zabana et al. Gastroenterologia y Hepatologia
- P425 One-year outcomes of ustekinumab therapy in a multi-drug refractory Crohn's disease cohort
- (2013) D. Ginard et al. Journal of Crohns & Colitis
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab for Peristomal Pyoderma Gangrenosum
- (2012) Marianne Fahmy et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversible Posterior Leukoencephalopathy Syndrome in a Patient Treated With Ustekinumab
- (2011) David Gratton ARCHIVES OF DERMATOLOGY
- Lymphomatoid Drug Reaction to Ustekinumab
- (2011) Jae Jung ARCHIVES OF DERMATOLOGY
- Malignant melanoma during ustekinumab therapy of Crohnʼs disease
- (2011) Laura M. Ehmann et al. INFLAMMATORY BOWEL DISEASES
- Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials
- (2011) L. Guenther et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort
- (2010) Kelvin T. Thia et al. GASTROENTEROLOGY
- Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2
- (2010) Kristian Reich et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
- (2010) Richard G. Langley et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Anti-IL-12/23
- (2009) David Schwartz INFLAMMATORY BOWEL DISEASES
- Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohnʼs disease
- (2009) Bruce E. Sands et al. INFLAMMATORY BOWEL DISEASES
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now